Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FDJL3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,982
Award facts
- Contract value 100% obligated
- $34,982.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at approximately $35,000 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 mL vials. The award was issued on January 9, 2026, with an ultimate completion date of February 2, 2026, under a firm fixed-price contract structure without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical support to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has been registered in the System for Award Management since 2001 and serves as a critical supplier within the federal pharmaceutical supply chain, specializing in the distribution of branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to military healthcare operations. The company's PPV-G GEN V prime vendor contract, awarded in November 2025 with a ceiling value of $500 million and a performance period extending through December 2036, authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for recurring medical supply needs. This particular delivery order for Keytruda, an oncology treatment, exemplifies the breadth of DMS Pharmaceutical Group's pharmaceutical portfolio and its demonstrated capability to fulfill the specialized requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FDJL3?
SPE2DR26FDJL3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 9, 2026.
How much is contract SPE2DR26FDJL3 worth?
The government has obligated $34,982 on SPE2DR26FDJL3.
Is contract SPE2DR26FDJL3 an order under another contract?
Yes. SPE2DR26FDJL3 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJL3 competed?
The extent of competition for SPE2DR26FDJL3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award